First-line Furmonertinib in Advanced NSCLC Patients With EGFR Uncommon Mutation
Clinical trial NCT05548348 · UNKNOWN
Trial details
- NCT number
- NCT05548348
- Sponsor
- Chongqing University Cancer Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-09-26
- Primary completion
- 2023-12-31
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.